Estudio PERSIRIS: estudio observacional, postautorización, prospectivo, para evaluar la persistencia al tratamiento con risedronato mensual en mujeres con osteoporosis / PERSIRIS study: observational study, postmarketing, prospective, to evaluate the persistence to treatment with monthly risedronate in women with osteoporosis

OBJETIVO: Evaluar la persistencia del tratamiento con risedronato mensual y conocer los motivos de persistencia y no persistencia terapéutica y el perfil de las pacientes no persistentes. DISEÑO: Estudio observacional, postautorización y prospectivo. Emplazamiento: Consultas de atención primaria, traumatología, reumatología, ginecología y geriatría de Cataluña. PARTICIPANTES: Mujeres con osteoporosis en tratamiento con risedronato mensual que previamente hubiesen abandonado el tratamiento con bifosfonato semanal. MEDICIONES PRINCIPALES: Porcentaje de pacientes bajo risedronato mensual persistentes al año de su prescripción, motivos de persistencia y no persistencia y perfil de pacientes no persistentes en relación a datos biodemográficos, datos clínicos y factores de riesgo de fractura. RESULTADOS: Doscientos ochenta y nueve pacientes valorables con una edad media de 68,3. A los 12 meses de inicio de risedronato mensual, un 58,1% de las pacientes persistía con el tratamiento. Motivos más frecuentes de abandono: miedo a tener efectos secundarios y creencia de que la enfermedad es propia de la edad. Motivos de persistencia destacables: comodidad/facilidad y posología. Se observaron diferencias significativas entre pacientes persistentes y no persistentes en relación a: situación laboral, número de tratamientos concomitantes y talla; sin embargo los resultados de posibles factores asociados deben contextualizarse dentro de las características del estudio y la diferencia de talla no parece clínicamente relevante. CONCLUSIONES: La administración de pautas terapéuticas más cómodas, como risedronato mensual en la osteoporosis, podría facilitar la persistencia en los pacientes mejorando la efectividad del fármaco. Sin embargo, en dicha persistencia pueden influir también variables biodemográficas y clínicas de diversa índole

OBJECTIVE: To assess the persistence of treatment with monthly risedronate and know the reasons of persistence and nontherapeutic persistence and the profile of the non-persistent patients. Desing: Observational, postmarketin and prospective study. LOCATION: Primary care, traumatology, rheumatology, gynecology and geriatrics of Catalonia. PARTICIPANTS: Women with osteoporosis treated with monthly risedronate that previously had abandoned weekly bisphosphonate therapy. MAIN MEASUREMENTS: Percentage of patients on persistent monthly risedronate year of their prescription, reasons for persistent and non persistent and profile of non persistent patients in relation to biodemographic data, clinical data and risk factors for fracture. RESULTS: 289 evaluable patients with a mean age of 68.3. At 12 months of initiation with monthly risedronate, 58.1% of patients remained on treatment. Most frequent reasons for leaving: fear of having side effects and belief that the disease is typical of the age. Reasons remarkable persistence: comfort/ease and dosage. Significant differences were observed between persistent and non-persistent patients relative to: employment status, number of concomitant therapy and height; however the results of possible associated factors must be contextualized within the study characteristics and the difference in size does not seem clinically relevant. CONCLUSIONS: The administration of therapeutic patterns more comfortable as monthly risedronate in osteoporosis, could facilitate persistence in patients improving the effectiveness of the drug. However in that persistence can also influence biodemographic and clinical variables and diverse of various kinds

[PERSIRIS study: observational study, postmarketing, prospective, to evaluate the persistence to treatment with monthly risedronate in women with osteoporosis]. / Estudio PERSIRIS: estudio observacional, postautorización, prospectivo, para evaluar la persistencia al tratamiento con risedronato mensual en mujeres con osteoporosis.

OBJECTIVE: To assess the persistence of treatment with monthly risedronate and know the reasons of persistence and nontherapeutic persistence and the profile of the non-persistent patients. DESING: Observational, postmarketin and prospective study. LOCATION: Primary care, traumatology, rheumatology, gynecology and geriatrics of Catalonia. PARTICIPANTS: Women with osteoporosis treated with monthly risedronate that previously had abandoned weekly bisphosphonate therapy. MAIN MEASUREMENTS: Percentage of patients on persistent monthly risedronate year of their prescription, reasons for persistent and non persistent and profile of non persistent patients in relation to biodemographic data, clinical data and risk factors for fracture. RESULTS: 289 evaluable patients with a mean age of 68.3. At 12 months of initiation with monthly risedronate, 58.1% of patients remained on treatment. Most frequent reasons for leaving: fear of having side effects and belief that the disease is typical of the age. Reasons remarkable persistence: comfort/ease and dosage. Significant differences were observed between persistent and non-persistent patients relative to: employment status, number of concomitant therapy and height; however the results of possible associated factors must be contextualized within the study characteristics and the difference in size does not seem clinically relevant. CONCLUSIONS: The administration of therapeutic patterns more comfortable as monthly risedronate in osteoporosis, could facilitate persistence in patients improving the effectiveness of the drug. However in that persistence can also influence biodemographic and clinical variables and diverse of various kinds.

[The influence of correct blood pressure measurement on the diagnostic decisions in hypertensive patients. MEDIDA study]. / Influencia de la medida correcta de la presión arterial en la toma de decisiones diagnósticas en la hipertensión arterial. Estudio MEDIDA.

BACKGROUND AND OBJECTIVE: We aimed to assess the influence of correct blood pressure (BP) measurement, following the recommendations of the Spanish Guideline of Hypertension 2005 (SGH), on the diagnostic decisions in hypertensive patients. PATIENTS AND METHOD: Prospective, longitudinal, observational, multicenter study conducted in hypertensive patients with stable pharmacologic therapy in primary care units. 4040 patients were included, in whom BP was measured following current clinical practice at the first visit (visit 1). After 7 days no therapeutic changes could be made and BP was measured following the criteria of good BP measurement from the SGH (visit 2). Control rate was assessed both, following the investigators opinion and the SGH algorithm, at visits 1 and 2. Differences in therapeutic recommendations between visits were assessed. RESULTS: 3436 patients were evaluable (48.9% women), with mean age (standard deviation) of 63.4 (11.4) years. Decreases in systolic/diastolic BP of 4.8 mmHg (95% confidence interval [CI], 4.5-5.1) and 2.8 mmHg (95% CI, 2.6-3.0) between visits were observed. The control rate following the investigators opinion was of 59.1% (95% CI, 57.4-60.8%) at visit 1 and 76.4% (95% CI, 75.0-77.9%) at visit 2, and the one following the criteria of the SGH was 32.2% (95% CI, 30.6-33.7%) at visit 1 and 46.6% (95% CI, 44.9-48.3%) at visit 2. The rate of patients in which therapeutic recommendations were changed was of 54.1% (95% CI, 52.4-55.7%). CONCLUSIONS: Applying the recommendations of the SHG for correct BP measurement led to increased control rate in relation to a previous measurement, prompting changes in the therapeutic attitude.

Influencia de la medida correcta de la presión arterial en la toma de decisiones diagnósticas en la hipertensión arterial. Estudio MEDIDA / The influence of correct blood pressure measurement on the diagnostic decisions in hypertensive patients. MEDIDA study

FUNDAMENTO Y OBJETIVO: El propósito del estudio ha sido cuantificar la influencia de la correcta medida de la presión arterial (PA), siguiendo las recomendaciones de la Guía Española de Hipertensión2005 (GETHA), sobre la toma de decisiones diagnósticas en hipertensos. PACIENTES Y MÉTODO: Se ha realizado un estudio prospectivo, longitudinal, observacional y multicéntrico en hipertensos con tratamiento farmacológico estable, en el ámbito de atención primaria. Se incluyó a 4.040 pacientes, a quienes se efectuaron 2 mediciones de la PA: la primera según la práctica habitual (visita 1) y la segunda al cabo de 7 días, sin ninguna modificación terapéutica, aplicando los criterios de la GEHTA sobre la medición correcta de la PA (visita 2). Se calculó la tasa de control según criterio de los investigadores y aplicando el algoritmo de la GEHTA, y se evaluaron las diferencias entre las recomendaciones terapéuticas efectuadas tras las visitas 1 y 2.RESULTADOS: Fueron valorables 3.436 pacientes (un 48,9% mujeres), con una edad media (desviación estándar) de 63,4 (11,4) años. Se observaron descensos de la PA sistólica y de la PA diastólica de 4,8 mmHg (intervalo de confianza [IC] del 95%, 4,5-5,1) y de 2,8 mmHg (IC del95%, 2,6-3,0), respectivamente, entre las visitas 1 y 2. A criterio de los investigadores, el porcentaje de control fue del 59,1% (IC del 95%, 57,4-60,8%) en la visita 1 y del 76,4% (IC del95%, 75,0-77,9%) en la visita 2 (p < 0,001), mientras que al aplicar los criterios de la GEHTA el grado de control fue del 32,2% (IC del 95%, 30,6-33,7%) y del 46,6% (IC del 95%, 44,9-48,3%), respectivamente (p < 0,001). El porcentaje de pacientes a los que se modificaron las recomendaciones terapéuticas fue del 54,1% (IC del 95%, 52,4-55,7%).CONCLUSIONES: La aplicación de las recomendaciones para la medida correcta de la PA incrementó el porcentaje de control respecto a una medida previa, lo que dio lugar a una modificación en la conducta terapéutica

BACKGROUND AND OBJECTIVE: We aimed to assess the influence of correct blood pressure (BP) measurement, following the recommendations of the Spanish Guideline of Hypertension 2005(SGH), on the diagnostic decisions in hypertensive patients. PATIENTS AND METHOD: Prospective, longitudinal, observational, multicenter study conducted in hypertensive patients with stable pharmacologic therapy in primary care units. 4040 patients were included, in whom BP was measured following current clinical practice at the first visit(visit 1). After 7 days no therapeutic changes could be made and BP was measured following the criteria of good BP measurement from the SGH (visit 2). Control rate was assessed both, following the investigators opinion and the SGH algorithm, at visits 1 and 2. Differences in therapeutic recommendations between visits were assessed. RESULTS: 3436 patients were evaluable (48.9% women), with mean age (standard deviation) of63.4 (11.4) years. Decreases in systolic/diastolic BP of 4.8 mmHg (95% confidence interval [CI],4.5-5.1) and 2.8 mmHg (95% CI, 2.6-3.0) between visits were observed. The control rate following the investigators opinion was of 59.1% (95% CI, 57.4-60.8%) at visit 1 and 76.4% (95%CI, 75.0-77.9%) at visit 2, and the one following the criteria of the SGH was 32.2% (95% CI,30.6-33.7%) at visit 1 and 46.6% (95% CI, 44.9-48.3%) at visit 2. The rate of patients in which therapeutic recommendations were changed was of 54.1% (95% CI, 52.4-55.7%).CONCLUSIONS: Applying the recommendations of the SHG for correct BP measurement led to increased control rate in relation to a previous measurement, prompting changes in the therapeutic attitude